GlassScriptPhysician profile
Ezra Israel
NPI 1073759346
$7,591.78
in general payments reported to CMS, 2019-2025
34 companies · $957 in 2025
The $957 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $598 · 2021: $1,013 · 2022: $1,126 · 2023: $1,518 · 2024: $2,012 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,079 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,078.58 |
| Education | $409.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,098.96 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Vifor Pharma, INC. | $547.54 | 2019-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $537.14 | 2019-2025 | Rayaldee |
| Horizon Therapeutics Plc | $517.05 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $488.87 | 2020-2024 | Benlysta, Jesduvroq |
| Novo Nordisk INC | $456.16 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Hospital Products INC. | $433.23 | 2022-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.06 | 2019-2025 | Jardiance |
| Genzyme Corporation | $351.30 | 2023-2025 | |
| Lilly USA, LLC | $333.20 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $295.90 | 2021-2025 | |
| Amgen INC. | $295.16 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $282.84 | 2020-2023 | Jynarque |
| Akebia Therapeutics INC | $259.32 | 2019-2024 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $240.91 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $124.29 | 2022-2024 | Velphoro |
| Abbott Laboratories | $112.11 | 2021-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $81.50 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $78.43 | 2022-2024 | Camzyos, Eliquis |
| Aurinia Pharma U.S., INC. | $67.58 | 2023-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $65.28 | 2023-2024 | Tarpeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.96 | 2020-2024 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $61.18 | 2023 | Dupixent |
| Ardelyx, INC. | $59.36 | 2023-2024 | Ibsrela |
| Dexcom, INC. | $56.97 | 2021-2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $50.46 | 2024-2025 | |
| Corcept Therapeutics | $47.36 | 2024 | Korlym |
| Abbvie INC. | $41.54 | 2023-2024 | |
| Pfizer INC. | $36.85 | 2022-2023 | |
| Astellas Pharma US INC | $35.19 | 2024-2025 | Veozah |
| Intra-Sana Laboratories | $33.32 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Xeris Pharmaceuticals, INC. | $23.48 | 2024 | Keveyis |
| Grt US Holding, INC. | $22.28 | 2022 | |
| Bardy Diagnostics, INC. | $16.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ezra Israel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.